Get the Stockscreener App
0.91
1.11%
0.01
After Hours:
.92
0.01
+1.10%
Genprex Inc stock is traded at $0.91, with a volume of 327.34K.
It is up +1.11% in the last 24 hours and down -17.27% over the past month.
Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's lead product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC.
See More
Previous Close:
$0.90
Open:
$0.8701
24h Volume:
327.34K
Relative Volume:
0.04
Market Cap:
$7.74M
Revenue:
-
Net Income/Loss:
$-31.45M
P/E Ratio:
-1.4677
EPS:
-0.62
Net Cash Flow:
$-24.56M
1W Performance:
-21.55%
1M Performance:
-17.27%
6M Performance:
-55.61%
1Y Performance:
-89.66%
1-Day Range:
$0.8578
$0.9617
1-Week Range:
$0.8204
$1.26
52-Week Range:
$0.2806
$335.84
Genprex Inc Stock (GNPX) Company Profile
Name
Genprex Inc
Sector
Industry
Phone
512-537-7997
Address
1601 TRINITY STREET, BLDG. B, AUSTIN, TX
Compare GNPX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GNPX
Genprex Inc
|
0.91 | 7.74M | 0 | -31.45M | -24.56M | -24.40 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Genprex Inc Stock (GNPX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-26-21 | Initiated | National Securities | Buy |
| Apr-29-19 | Initiated | Noble Capital Markets | Outperform |
Genprex Inc Stock (GNPX) Latest News
SEC Form 424B5 filed by Genprex Inc. - Quantisnow
Genprex Completes Phase 1 Dose Escalation of Acclaim-3 Clinical Trial for ES-SCLC PatientsGenprex, Inc. (NASDAQ:GNPX) announced in a press release dated December 16, 2024, the successful completion of the Phase 1 dose escalation segment of the - Defense World
Genprex advances to phase 2 in lung cancer trial - Investing.com
Genprex Receives Safety Review Committee Approval to Advance to Phase 2 Portion of Acclaim-3 Clinical Trial of Reqorsa® Gene Therapy in Combination with Tecentriq® in Extensive Stage Small Cell Lung Cancer - PR Newswire
Genprex to Present and Participate at Upcoming September Investor and Industry Conferences - The Eastern Progress Online
Genprex to Participate in 2024 BIO Europe Conference - The Eastern Progress Online
Genprex Collaborators Present Positive Preclinical Data on the U - GuruFocus.com
Genprex Collaborators to Present Positive Preclinical Data on th - GuruFocus.com
Genprex links with University of Michigan on lung cancer treatment - Yahoo Finance
Genprex secures exclusive gene therapy license for cancer By Investing.com - Investing.com Canada
Genprex secures exclusive gene therapy license for cancer - Investing.com India
Genprex Secures Global Patent Rights for Breakthrough Lung Cancer Gene Therapy | GNPX Stock News - StockTitan
Genprex faces Nasdaq delisting over equity shortfall By Investing.com - Investing.com Australia
Genprex faces Nasdaq delisting over equity shortfall - Investing.com India
U.S. Stock market top gainers: Mullen Automotive gains 92.92% while Genprex increases by 54.48% during mid day trading - Business Upturn
'Animal spirits' set to drive S&P 500 to 6,600 by mid-2025, Evercore says - Investing.com
Genprex reports promising preclinical data on cancer therapy - Investing.com
Genprex Collaborators Present Positive Preclinical Data on Reqorsa® Gene Therapy at the Society for Immunotherapy of Cancer 2024 Annual Meeting - BioSpace
Genprex Featured in CEO/CFO Magazine Discussing Novel Gene Thera - GuruFocus.com
Genprex regains Nasdaq compliance with bid price rule - Investing.com India
Genprex regains Nasdaq compliance with bid price rule By Investing.com - Investing.com Australia
Genprex reports promising preclinical data on cancer therapy By Investing.com - Investing.com UK
Genprex Announces Sponsored Research Agreement with The Universi - GuruFocus.com
Short Interest in Genprex, Inc. (NASDAQ:GNPX) Increases By 5.2% - Defense World
Investor Excitement Sparks Genprex (GNPX) Stock Rally - Stocks Telegraph
Genprex reports positive preclinical gene therapy data By Investing.com - Investing.com South Africa
Genprex reports positive preclinical gene therapy data - Investing.com India
Genprex Collaborators Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer, Mesothelioma and Glioblastoma - The Malaysian Reserve
Genprex (NASDAQ:GNPX) Announces Sponsored Research Agreement with University of Michigan Rogel Cancer Center for Study on TUSC2 Gene Therapy in ALK-Positive Lung Cancer Patients - Defense World
U.S. stocks mixed at close of trade; Dow Jones Industrial Average down 0.80% - MSN
Genprex explores gene therapy in lung cancer study - Investing.com India
Genprex explores gene therapy in lung cancer study By Investing.com - Investing.com South Africa
Genprex signs two lung cancer research agreements - TipRanks
Genprex Announces Sponsored Research Agreement with The University of Michigan Rogel Cancer Center and Lung Cancer Study Collaboration with ALK Positive - StreetInsider.com
3 Penny Stocks to Watch Now, 10/24/24 - TipRanks
U.S. stocks mixed at close of trade; Dow Jones Industrial Average down 0.02% - MSN
2 No-Brainer Artificial Intelligence (AI) Stocks to Buy Right Now - Yahoo Finance
Dow Falls Over 150 Points; General Motors Tops Q3 Views - Benzinga
‘Permanent should mean Permanent’: Purbeck calls for commitment to Full Expensing - Yahoo! Voices
TD Bank becomes liquidity provider for LTX - Yahoo! Voices
UK economy 'set to accelerate', says IMF - Yahoo! Voices
IMF's economic view: A brighter outlook for US but still-tepid global growth - Yahoo! Voices
Scotch whisky business Compass Box in overseas push - Yahoo News
Siemens secures contract to optimise Unibuss’ electric fleet with Depot360 - Yahoo! Voices
US dough business Urban Farmer appoints Chris Jaromin as new CEO - Yahoo! Voices
DHL Supply Chain to close Canal Winchester warehouse, lay off more than 150 workers - Yahoo News
QC Copper to acquire remaining 50% of Roger Gold-Copper Project - Yahoo! Voices
CAC introduces cyber cover for energy and utility sectors - Yahoo! Voices
How small Canadian retailers are thriving on multiple sales channels - Yahoo! Voices
Zymeworks doses first subject in Phase I trial of ZW171 for various forms of cancer - Yahoo! Voices
Genprex Inc Stock (GNPX) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.88%
2.65%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):